Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive
Australian company Vaxxas receives significant investment from Endpoints Capital
October 1, 2024 Australian Biotech
Latest Video
New Stories
-
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 12, 2025 - - Latest News -
Rare Cancers Australia says election is the chance to end the ‘cancer lottery’
February 12, 2025 - - Latest News -
Specialised Therapeutics announces Thai approval of breast cancer therapy
February 12, 2025 - - Latest News -
Merck adds experienced industry executive to leadership team
February 11, 2025 - - Latest News -
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - - Latest News -
AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies
February 11, 2025 - - Latest News -
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 - - Latest News